Streetbeat News

Products Services

FOUR

The Indianapolis Colts have partnered with Shift4 to implement end-to-end payment solutions for ticketing transactions at Lucas Oil Stadium starting in the 2024 season.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:06 pm

CODI

Compass Diversified's subsidiary, Altor Solutions, has entered into a definitive agreement to acquire Lifoam Industries for $137 million in cash. Lifoam, a manufacturer of temperature-controlled shipping solutions, will enhance Altor's offerings in the industrial and life sciences markets.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:06 pm

ALZN

Alzamend Neuro has partnered with Massachusetts General Hospital for a Phase II study of AL001 for PTSD treatment. The study will be led by Harvard Associate Professor Dr. Ovidiu Andronesi and will compare AL001 to marketed lithium carbonate in the human brain.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:04 pm

CCG

Cheche Group has expanded its partnership with ARCFOX and launched a full-service insurance platform. The company also plans to offer ancillary products such as GAP and extended warranty insurance.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:03 pm

PCSA

Processa Pharmaceuticals (NASDAQ: PCSA) reports positive preclinical data for its Next Generation irinotecan (NGC-Iri), showing it delivers more cancer-killing SN-38 molecules to tumors with fewer side effects compared to irinotecan and Onivyde. The studies suggest NGC-Iri could be a more effective and safer cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:02 pm

AKTX

Akari Therapeutics received positive Pre-IND feedback from the FDA for its eye disease treatment, PAS-nomacopan. This feedback clarifies the company's preclinical plans, drug manufacturing, and Phase 1 clinical strategy. The IND is expected to be submitted in 2025.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:02 pm

ACN

Accenture (NYSE:ACN) has invested in Earli Inc., a biotech company specializing in early cancer detection. This strategic investment aims to expand collaborations with global health and pharma companies, enhancing cancer detection and treatment capabilities.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:00 pm

LQDA

Liquidia shares are trading lower after the FDA granted tentative approval for YUTREPIA inhalation powder to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 11:55 am

SPRC

SciSparc Ltd. (NASDAQ: SPRC) has signed an exclusive patent license agreement with Polyrizon Ltd to out-license its SCI-160 program for pain treatment. SciSparc will receive Polyrizon securities valued at $3 million and potentially milestone fees and royalties. SCI-160 has shown promising preclinical results. Additionally, SciSparc has agreed to a merger with AutoMax Motors Ltd. SPRC stock is up 21.8% in premarket trading.

Portfolio Pulse from Vandana Singh

August 19, 2024 | 11:51 am

AMZN

COST

CVS

WBA

WMT

Retail pharmacy chains like CVS Health and Walgreens Boots Alliance are facing significant challenges due to shifting consumer habits, operational inefficiencies, and financial pressures. Declining prescription drug reimbursement rates, competition from e-commerce giants like Amazon, and inflation are eroding profit margins. CVS is dealing with losses in its insurance business and has announced cost cuts, while Walgreens is struggling with its primary care push. Both companies are seeing reduced sales as consumers turn to cheaper alternatives like Walmart and Costco.

Portfolio Pulse from Vandana Singh

August 19, 2024 | 11:43 am